Acrivon Therapeutics Inc (ACRV) Stock Price, Quote & News

Company Profile

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 207 8979

Website: acrivon.com

Address:

480 Arsenal Way, Suite 100, Watertown, United States

hpulse Jan. 15 at 12:54 AM

$ACRV Let’s go for $2.50 tomorrow! Ready to spike!

0 · Reply

UltimateTrader_22 Jan. 14 at 11:47 PM

$ACRV bullish reversal. Get news and could fill the gap with shortsqueeze. @TraderNice

1 · Reply

TraderNice Jan. 14 at 11:11 PM

$ACRV Tomorrow we should be looking as the support at 1.82 and our goal 2.00 range…resistance…..the borrower rate is very high

1 · Reply

BuyThemCheapStackemDeep Jan. 14 at 10:57 PM

$ACRV Keep it pushing ⬆️!

0 · Reply

TraderNice Jan. 14 at 10:52 PM

$ACRV ACRV currently has high short interest, a very high borrow rate, rising prices, higher volume, and no strong downside, which makes shorts uncomfortable.

0 · Reply

Poor_and_Stupid Jan. 14 at 10:27 PM

$ACRV

0 · Reply

Jmyoob Jan. 14 at 10:20 PM

$ACRV The End of Villain

1 · Reply

LogicalTrading Jan. 14 at 10:18 PM

$ACRV tomorrow $2

0 · Reply

TraderNice Jan. 14 at 10:07 PM

$ACRV The cost of borrowing has skyrocketed today! Earlier today, the borrowing cost was around 17-18%. But now, it’s a whopping 47.63%! This huge jump means that shares are becoming very rare to borrow. When there’s a lot of demand to short a stock but not enough lendable shares, brokers raise the borrowing fee. Here’s how this affects short sellers: Holding a short becomes very expensive. Traders might close their shorts quickly to avoid paying the higher fee.

0 · Reply

jdkd4 Jan. 14 at 10:04 PM

$ACRV @jacksparo Been working all day, no time to check the markets. Such a nice feeling that I have Jack sparrow doing my due diligence for me and making me money even when I’m not paying attention!!!!!

1 · Reply

Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls

Jan 8, 2026, 7:30 AM EST - 6 days ago

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

Jan 6, 2026, 7:30 AM EST - 8 days ago

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Dec 17, 2025, 9:34 AM EST - 4 weeks ago

UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Nov 13, 2025, 4:10 PM EST - 2 months ago

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 22, 2025, 4:15 PM EDT - 3 months ago

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

Oct 1, 2025, 4:30 PM EDT - 3 months ago

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 13, 2025, 4:15 PM EDT - 5 months ago

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

May 14, 2025, 4:10 PM EDT - 8 months ago

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Apr 25, 2025, 8:00 AM EDT - 9 months ago

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Apr 7, 2025, 4:05 PM EDT - 10 months ago

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Mar 27, 2025, 5:44 PM EDT - 10 months ago

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 19, 2025, 8:00 AM EDT - 10 months ago

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Dec 12, 2024, 3:25 PM EST - 1 year ago

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Sep 18, 2024, 10:11 AM EDT - 1 year ago

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Sep 14, 2024, 3:10 AM EDT - 1 year ago

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Jun 13, 2024, 2:00 PM EDT - 1 year ago

Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?

May 29, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Apr 24, 2024, 7:16 PM EDT - 1 year ago

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Apr 16, 2024, 8:01 PM EDT - 1 year ago

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Apr 3, 2024, 3:07 AM EDT - 1 year ago

What To Buy After You Sell The Russell 2000

AVUV IJR IWM IWN MLYS NXT SKWD

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 5, 2024, 4:30 PM EST - 2 years ago

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Feb 27, 2024, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 12, 2024, 4:00 PM EST - 2 years ago

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 21, 2023, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Nov 9, 2023, 8:01 AM EST - 2 years ago

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 19, 2023, 4:32 PM EDT - 2 years ago

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Sep 5, 2023, 4:05 PM EDT - 2 years ago

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jun 22, 2023, 4:00 PM EDT - 2 years ago

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Mar 28, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Mar 26, 2023, 9:53 AM EDT - 3 years ago

Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Mar 6, 2023, 8:00 AM EST - 3 years ago

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Nov 14, 2022, 10:16 PM EST - 3 years ago

Acrivon Therapeutics Announces Pricing of Initial Public Offering

Nov 3, 2022, 7:52 AM EDT - 3 years ago

Acrivon Therapeutics sets IPO price range

Oct 19, 2022, 11:50 AM EDT - 3 years ago

Acrivon Therapeutics Begins U.S. IPO Rollout

hpulse Jan. 15 at 12:54 AM

$ACRV Let’s go for $2.50 tomorrow! Ready to spike!

0 · Reply

UltimateTrader_22 Jan. 14 at 11:47 PM

$ACRV bullish reversal. Get news and could fill the gap with shortsqueeze. @TraderNice

1 · Reply

TraderNice Jan. 14 at 11:11 PM

$ACRV Tomorrow we should be looking as the support at 1.82 and our goal 2.00 range…resistance…..the borrower rate is very high

1 · Reply

BuyThemCheapStackemDeep Jan. 14 at 10:57 PM

$ACRV Keep it pushing ⬆️!

0 · Reply

TraderNice Jan. 14 at 10:52 PM

$ACRV ACRV currently has high short interest, a very high borrow rate, rising prices, higher volume, and no strong downside, which makes shorts uncomfortable.

0 · Reply

Poor_and_Stupid Jan. 14 at 10:27 PM

$ACRV

0 · Reply

Jmyoob Jan. 14 at 10:20 PM

$ACRV The End of Villain

1 · Reply

LogicalTrading Jan. 14 at 10:18 PM

$ACRV tomorrow $2

0 · Reply

TraderNice Jan. 14 at 10:07 PM

0 · Reply

jdkd4 Jan. 14 at 10:04 PM

1 · Reply

spoon7896 Jan. 14 at 9:49 PM

$ACRV fundamentals haven’t changed

0 · Reply

Beepers333 Jan. 14 at 9:03 PM

$ACRV Nice close👍

1 · Reply

Pittsburghgirl Jan. 14 at 8:59 PM

$ACRV

0 · Reply

Dou_said_it Jan. 14 at 8:57 PM

$ACRV maybe there is a 1 to 1 meeting in JPM … maybe acrv negociate a partnership …

1 · Reply

PLATINUM_TRADES Jan. 14 at 8:56 PM

$ACRV I told u!! Where's my $2.00!

1 · Reply

Dou_said_it Jan. 14 at 8:55 PM

$ACRV hold guys, hooold

0 · Reply

Manonfire8 Jan. 14 at 8:54 PM

$ACRV game time!

0 · Reply

Razied Jan. 14 at 8:54 PM

$ACRV short squeeze time? 👀

0 · Reply

Rachs88 Jan. 14 at 8:53 PM

$ACRV this for those who held, this should fly soon. Good luck

1 · Reply

Dou_said_it Jan. 14 at 8:51 PM

$ACRV goood, this will rich 2$ next week

0 · Reply

BuyThemCheapStackemDeep Jan. 14 at 8:45 PM

$ACRV Drop an update PR already. Our patience deserves to be rewarded. 😎

2 · Reply

UltimateTrader_22 Jan. 14 at 8:14 PM

$ACRV "The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush" Link: https://www.barchart.com/story/news/37041532/the-69b-precision-pivot-why-biomarker-platforms-are-igniting-a-new-oncology-gold-rush Acrivon Therapeutics (NASDAQ:ACRV) announced positive data from its ACR-368 Phase 2b trial in endometrial cancer, showing a 39% overall response rate in OncoSignature-positive patients with a 67% confirmed response rate in BM-positive patients with serous subtype. The company has expanded the trial into the European Union across more than 20 sites in Germany, Italy, France and Spain. "We are particularly excited by the observation from our ongoing ACR-368 Phase 2 trial that subjects with serous endometrial cancer with up to two prior lines of therapy are showing over 50% confirmed response rate," said Peter Blume-Jensen, M.D., Ph.D., CEO, President and co-founder of Acrivon Therapeutics. The company has also submitted a Phase 3 confirmatory protocol to the FDA for ACR-368

1 · Reply

Market Cap	51.44M
Revenue (ttm)	0.00
Net Income (ttm)	-80.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,105,000
Avg Vol	1,889,778
Day's Range	N/A - N/A
Shares Out	31.56M
Stochastic %K	7%
Beta	1.73
Analysts	Strong Sell
Price Target	$11.50